I'm not sure why anyone would use an inferior drug like this one or macugen as maintenance, instead of using Lucentis upfront and as maintenance. There appear to be no safety concerns and the price is not that high (IMHO). Most of these pts are covered by Medicare(who currently doesn't account for cost when deciding to reimburse) and most have 2ndary insurance. A freind at ASRS suggest that acuity plans to run a trial in combo with Lucentis as they state the MOA is very different and may be synergistic. AS a single agent, Bevasiranib is dead IMHO.
Market Data 
Markets 
AI
